ICPT Intercept Pharmaceuticals Inc

Price (delayed)

$18.20

Market cap

$603.4M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.73

Enterprise value

$1.07B

Sector: Healthcare
Industry: Biotechnology

Highlights

The EPS has grown by 37% year-on-year and by 19% since the previous quarter
The net income has grown by 36% year-on-year and by 19% since the previous quarter
The quick ratio has declined by 21% year-on-year but it is up by 9% since the previous quarter
The equity has contracted by 20% from the previous quarter
ICPT's debt is up by 5% year-on-year

Key stats

What are the main financial stats of ICPT
Market
Shares outstanding
33.15M
Market cap
$603.4M
Enterprise value
$1.07B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.33
Earnings
Revenue
$321.7M
EBIT
-$173.62M
EBITDA
-$164.33M
Free cash flow
-$129.78M
Per share
EPS
-$6.73
Free cash flow per share
-$3.92
Book value per share
-$6.06
Revenue per share
$9.71
TBVPS
$15.69
Balance sheet
Total assets
$520.11M
Total liabilities
$720.11M
Debt
$568.11M
Equity
-$200M
Working capital
$341.33M
Liquidity
Debt to equity
-2.84
Current ratio
3.33
Quick ratio
3.15
Net debt/EBITDA
-2.85
Margins
EBITDA margin
-51.1%
Gross margin
98.4%
Net margin
-69.1%
Operating margin
-55.1%
Efficiency
Return on assets
-38.2%
Return on equity
N/A
Return on invested capital
-19.1%
Return on capital employed
-46.4%
Return on sales
-54%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ICPT stock price

How has the Intercept Pharmaceuticals stock price performed over time
Intraday
7.37%
1 week
-5.01%
1 month
-17.91%
1 year
-79.88%
YTD
-26.32%
QTD
-21.14%

Financial performance

How have Intercept Pharmaceuticals's revenue and profit performed over time
Revenue
$321.7M
Gross profit
$316.42M
Operating income
-$177.14M
Net income
-$222.32M
Gross margin
98.4%
Net margin
-69.1%
Intercept Pharmaceuticals's operating margin has surged by 52% YoY and by 26% QoQ
ICPT's net margin is up by 46% year-on-year and by 21% since the previous quarter
Intercept Pharmaceuticals's operating income has increased by 43% YoY and by 23% QoQ
The net income has grown by 36% year-on-year and by 19% since the previous quarter

Growth

What is Intercept Pharmaceuticals's growth rate over time

Valuation

What is Intercept Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
1.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.33
The EPS has grown by 37% year-on-year and by 19% since the previous quarter
The equity has contracted by 20% from the previous quarter
ICPT's price to sales (P/S) is 97% lower than its 5-year quarterly average of 62.1 and 51% lower than its last 4 quarters average of 3.8
ICPT's revenue is up by 18% year-on-year and by 2.9% since the previous quarter

Efficiency

How efficient is Intercept Pharmaceuticals business performance
The ROS has soared by 51% year-on-year and by 26% since the previous quarter
Intercept Pharmaceuticals's return on invested capital has increased by 31% YoY and by 20% QoQ
Intercept Pharmaceuticals's return on assets has increased by 15% YoY and by 14% QoQ

Dividends

What is ICPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ICPT.

Financial health

How did Intercept Pharmaceuticals financials performed over time
The total assets is 28% smaller than the total liabilities
Intercept Pharmaceuticals's current ratio has decreased by 21% YoY but it has increased by 9% from the previous quarter
The quick ratio has declined by 21% year-on-year but it is up by 9% since the previous quarter
Intercept Pharmaceuticals's debt to equity has surged by 82% YoY and by 15% QoQ
The equity has contracted by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.